Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback

Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more...